美股异动 | Eikon Therapeutics(EIKN.US)登陆纳斯达克 开盘跌超5%

智通财经
Feb 06

智通财经APP获悉,周四,Eikon Therapeutics(EIKN.US)登陆纳斯达克,开盘跌超5%,报17.05美元,IPO价格为18美元。Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立,公司目前正布局多款癌症实验性疗法研发管线。公司研发进度最快的候选药物EIK1001,正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期临床试验,该研究的中期分析数据预计将于2026年下半年公布。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10